Kodu・Aktsiate loetelu・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Suletud

SektorTervishoid

19.11 1.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.8

Max

19.34

Põhinäitajad
By Trading Economics
Sissetulek	-24M -54M
Müük	-2.5M 305M
Aktsiakasum	-0.15
Kasumimarginaal	-17.851
Töötajad	3,100
EBITDA	-24M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+175.38% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	11. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-1B 3.7B
Eelmine avamishind	17.95
Eelmine sulgemishind	19.11

Uudiste sentiment

By Acuity

100%

320 / 340 Pingereas Healthcare

Legend Biotech Corp ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31. juuli 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30. juuli 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29. juuli 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28. juuli 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27. juuli 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24. juuli 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22. juuli 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21. juuli 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20. juuli 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Võrdlus sarnastega

Hinnamuutus

Legend Biotech Corp ADR Prognoos

Hinnasiht

By TipRanks

175.38% tõus

12 kuu keskmine prognoos

Keskmine 52.35 USD 175.38%

Kõrge 80 USD

Madal 28 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Legend Biotech Corp ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Legend Biotech Corp ADR aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.